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Abstract
Atopic dermatitis (AD) patients mount IgE antibody responses to a variety of
environmental allergens and also to autoantigens. We analyzed serum samples
from four AD patients who had received oral cyclosporine A (CyA) treatment
for up to 17 months regarding IgE autoreactivity to nitrocellulose-blotted human
epithelial cell extracts and IgE levels to environmental allergens by quantitative
ImmunoCap measurements. Skin inflammation was assessed by SCORAD. Dur-
ing full-dose treatment, a strong reduction in T-cell-mediated skin symptoms was
observed which reappeared when CyA treatment was reduced or stopped. The
intensity of IgE autoreactivity seemed to follow skin inflammation as it was
reduced during full-dose treatment and increased upon inflammation. Interest-
ingly, IgE levels to exogenous allergens were boosted by allergen exposure,
declined thereafter, and seemed to be unaffected by CyA. Our data thus indicate
that allergen-specific IgE production is boosted by allergen contact and cannot be
reduced by CyA-mediated T-cell suppression.
Type I allergy is an IgE-mediated hypersensitivity disease
affecting almost 25% of the population in industrialized coun-
tries (1). Allergic sensitization occurs in genetically predis-
posed individuals early in childhood after allergen encounter
which leads to class-switching to IgE production, a process
that depends on T-cell help and production of Th2 cytokines
(2, 3). The analysis of IgE reactivities to multiple micro-
arrayed allergen molecules in follow-up serum samples
obtained from children during the first years of life in birth
cohort studies indicates that IgE sensitizations to new aller-
gens become detectable during the first years of life indicating
that the children expand their IgE reactivity profiles (4, 5). By
contrast, IgE reactivity profiles in adult allergic patients
remain stable and only allergen-specific IgE levels change
depending on allergen exposure (6, 7). Using different
experimental models, evidence has been provided that the
secondary IgE production in sensitized allergic subjects or ani-
mals does not require T-cell help. For example, it has been
demonstrated that primary allergic sensitization can be pre-
vented by co-stimulation blockade, whereas secondary IgE
production is not affected in a murine model of grass pollen
allergy (8). In a clinical study, it has been shown that only
intact, IgE-reactive allergens but not T-cell epitope-contain-
ing, non-IgE-reactive allergen fragments boost secondary IgE
production in allergic patients (9). Furthermore, it has been
shown that HIV-infected patients with low CD4 cell counts
continue to produce allergen-specific IgE antibodies and that
allergen-specific IgE production can be boosted by allergen
exposure in these patients (10).
In this study, we had the opportunity to investigate the
effects of treatment with systemic cyclosporine A, a T-cell-
targeting drug on allergen-specific IgE production. Sera from
patients with atopic dermatitis who had received systemic
CyA treatment for up to 17 months were studied regarding
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Allergy
IgE reactivity to exogenous, respiratory allergens and
autoantigens.
Materials and methods
Characterization of patients and sera
Residual serum samples from four atopic dermatitis patients,
three males, one female, aged between 31 and 54, fulfilling
the clinical and morphological criteria of AD (11) and atopic
skin diathesis (12) were investigated in the study. These
patients had participated in a study from 1993 to 1995 com-
paring the efficacy and tolerability of two CyA formulations:
Sandimmun and Sandimmun Neoral, a micro-emulsion of
CyA with improved pharmacokinetic properties (13). In the
course of this study, patients were treated systemically with
CyA over time periods of 14–17 months. During the first
4 months, patients received doses between 3.7 and 4.4 mg/kg
bodyweight per day which were then reduced and stopped
after 11–13 further months (Figs 1, 2 and S1, S2). Other
treatments for AD were stopped 2 weeks before the onset of
the CyA medication. The anonymous analysis of serum sam-
ples was approved by the local ethics committee. Quantitative
measurements of allergen-specific IgE antibodies (rBet v 1,
rPhl p 1, rPhl p 5, mite allergens: Dermatophagoides
pteronyssinus) were performed using the CAP FEIA system
(Thermo Fisher, Uppsala, Sweden). Clinical staging was done
according to the criteria of Hanifin and Rajka (11). Disease
activity was estimated using the SCORAD as described (14).
SDS-PAGE, IgE immunoblotting
The human epithelial cell line A431 was obtained from the
American Type Culture Collection (ATCC, Rockville, MD,
USA). Cells were cultured and proteins extracted as
described (15). Protein extracts were separated by preparative
12.5% SDS-PAGE and blotted onto nitrocellulose mem-
branes (Schleicher & Schuell, Dassel, Germany). Membrane
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Figures 1 and 2 Time courses (x-axes) of cyclosporin A treatment,
skin symptoms, and IgE antibody reactivities to autoallergens and
exogenous allergens in two AD patients. (A) Cyclosporin A dose
(y-axes: mg/kg bodyweight/day), (B) SCORAD documentation of
skin manifestations (y-axis: SCORAD indices), and (C) IgE autoreac-
tivity to nitrocellulose-blotted human epithelial cell extracts are
displayed for different time points of blood sampling. Molecular
weights (kDa) are shown at the left margin and (D) time course of
specific serum IgE levels (y-axes: kUA/L) to exogenous allergens
(mite allergens, recombinant major birch pollen allergen, rBet v 1,
and two recombinant major timothy grass pollen allergens, rPhl p 1
and rPhl p 5).
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strips were incubated with serum samples (1:10 dilution) that
had been collected at different time points. Bound IgE
antibodies were detected with 125I-labeled antihuman IgE
antibodies (RAST, Pharmacia Diagnostics) as described (16).
Results
Systemic CyA treatment improves skin symptoms in AD
patients which is accompanied by a reduction in IgE
autoreactivity
A strong improvement of skin symptoms as reflected by a
reduction in the SCORAD was observed when patients
received full-dose CyA treatment during the first 4 months
(Figs 1B, 2B and S1B, S2B). The reduction of the CyA dose
and stopping of the treatment was accompanied by an increase
in the SCORAD and deterioration of skin inflammation. The
intensity of IgE autoreactivity to nitrocellulose-blotted cell
extracts seemed to reflect skin inflammation. For example, IgE
autoreactivity to a 38-kDa band recognized by patient 1 at the
beginning of treatment was high when the SCORAD was high
and disappeared for the remaining treatment period when the
SCORAD was low (Fig. 1B, C). Similar observations were
made for patients 2 and 3. IgE autoreactivity to a 70-kDa and
21-kDa band became weaker after treatment was started and
appeared again when the SCORAD rose between March and
September 1995 and in the end of the treatment in patient 2
(Fig. 2B, C). Also in patient 3, IgE autoreactivity to a 35-kDa
band disappeared when the SCORAD dropped and reap-
peared when it went up again (Fig. S1B, C). IgE autoreactivity
in patient 4 was not very intensive but also became weaker
after initiation of treatment (Fig. S2B, C).
IgE levels specific for exogenous inhaled allergens are
unaffected by CyA treatment
Strong increases of Bet v 1-specific IgE levels were observed in
the birch pollen allergic patient 2 shortly after the birch pollen
seasons during the observation period (i.e., 24.03., 14.05.;
Fig. 2D). Likewise, we found strong increases of grass pollen
allergen (i.e., rPhl p 1, rPhl p 5)-specific IgE levels in each of
the grass pollen allergic patients after the respective grass pol-
len seasons (July–September) which then declined again
(Figs 1D, 2D and S1D, S2D). The levels of IgE against house
dust mite allergens, a perennial allergen source, were rather
stable (e.g., patient 1: Fig. 1D) or showed some alterations
(e.g., patients 3 and 4: Figs S1D and S2D). Changes of IgE
levels to exogenous allergens thus seemed to be associated with
allergen contact and were not associated with CyA treatment.
Discussion
In this study, we analyzed IgE reactivity against endogenous
and exogenous allergens in AD patients who had received sys-
temic CyA treatment for up to 17 months (13). Systemic CyA
has a strong immunosuppressive effect on T cells and therefore
is used for the treatment of T-cell-mediated hypersensitivity
diseases, transplant rejection, and graft-versus-host reactions
(17). The systemic CyA treatment also led to a strong improve-
ment of T-cell-mediated skin symptoms in the studied AD
patients which was reflected by a strong drop of the SCORAD
after treatment was initiated. When we compared skin symp-
toms and IgE autoreactivity, we noted that the reduction in
skin inflammation was followed by a reduction in IgE autore-
activity which reappeared when the dose of CyA was reduced
and skin symptoms worsened again. We have observed a simi-
lar association of IgE autoreactivity and skin inflammation
earlier in another patient who was monitored regarding IgE
autoreactivity over an extensive period (18). In this patient, we
also noted that aggravation of skin inflammation was followed
by an increase in IgE autoreactivity, whereas improvement of
skin symptoms was followed by a decrease in IgE autoreactiv-
ity. We therefore think that tissue damage leads to the release
of autoantigens which then triggers the production of autore-
active IgE antibodies and thus mirrors tissue damage. A reduc-
tion in skin inflammation by CyA treatment would thus lead
to reduced release of autoantigens and thus explain the drop of
IgE autoreactivity. However, also other mechanisms may influ-
ence IgE autoreactivity such as IL-33-mediated stimulation of
pro-inflammatory cytokines or skin inflammation induced by
exposure to exogenous allergens (e.g., reappearance of IgE
autoantibodies after birch pollen exposure in patient 2; time
point 24. 03.; Fig. 2) (18, 19).
The kinetics and levels of IgE antibodies specific for envi-
ronmental allergens under CyA treatment have not yet been
investigated in any previous study and turned out to be
different from the kinetics and levels of IgE autoantibodies.
In fact, levels of birch and grass pollen allergen-specific IgE
followed allergen exposure. Pollen allergen-specific IgE
increased shortly after the pollen seasons and declined
thereafter similar as observed for patients suffering from
allergic rhinoconjunctivitis (7). Interestingly, increases of
pollen allergen-specific IgE levels were observed even when
patients had received high doses of systemic CyA and T-
cell-mediated skin inflammation had almost completely dis-
appeared. A possible explanation for this finding could be
that the boost of the secondary IgE production by pollen
allergen exposure leads to a direct stimulation of IgE pro-
duction by B cells without T-cell help. The assumption that
the boost of secondary IgE production may be independent
of T-cell help is in fact supported by other studies per-
formed in different experimental setups (8–10). Collectively,
these results indicate that it will be difficult to combat with
secondary IgE production in already sensitized allergic
patients with purely T-cell-targeting therapeutic strategies.
In fact, also co-stimulation blockade had no effects on IgE-
mediated asthma (20). We are well aware that the current
study has many limitations such as the low number of
patients and it is uncertain whether T-cell help was indeed
completely suppressed by CyA in the studied patients. Also,
no information regarding symptoms of respiratory allergy
was available for the patients. Nevertheless, our study
shows that even high doses of CyA do not suppress aller-
gen-specific IgE production in humans.
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Figures S1 and S2. Time courses of cyclosporin A treat-
ment, skin symptoms, and IgE antibody reactivities to
autoallergens and exogenous allergens in two AD patients.
(A) Cyclosporin A dose (y-axes: mg/kg bodyweight/day), (B)
SCORAD documentation of skin manifestations (y-axes:
SCORAD indices), (C) IgE auto-reactivity to nitrocellulose-
blotted human epithelial cell extracts are displayed for differ-
ent time points of blood sampling. Molecular weights (kDa)
are shown at the left margin and (D) time course of specific
serum IgE levels (y-axes: kUA/L) to exogenous allergens
(mite allergens and two recombinant major timothy grass
pollen allergens, rPhl p 1 and rPhl p 5). An arrow (“>“) indi-
cates the time point of tissue damage due to massive sun
exposure in patient 3.
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